Biologics

Three babies have been born after UC Davis Health providers performed the first spina bifida treatment combining surgery with stem cells.

Bone Biologics, which focuses on spinal orthobiologics, announced its underwritten public offering for $5.1 million total.

Precision Spine and HippoFi inked an agreement to help drive the sales of Pur Biologics products.

Pensacola, Fla.-based Andrews Medicine, led by James Andrews, MD, is partnering with Houston-based Celltex Therapeutics to form a biotechnology company focused on stem cell research and sports medicine.

From executive leadership moves to new product developments, here are key headlines about orthopedic regenerative medicine from the third quarter: 

A two-year study found Creative Medical Technology's StemSpine procedure was effective for treating lower back pain, the biologics company said Sept. 26.

A randomized controlled trial found Smith+Nephew's Regeneten bioinductive implant is effective at preventing retearing after a rotator cuff repair.

Ventris Medical's Amplify synthetic bone graft putty earned FDA 510(k) clearance.

Ortho Regenerative Technologies is now called ChitogenX, the company said Sept. 7.

From CEO moves to product debuts, here are seven developments from regenerative medicine companies since July 22.